Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- 3.1k Downloads
Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3ζ signaling is sufficient to elicit cytotoxicity and interferon-γ production while the additional provision of CD28-mediated signal 2 promotes T-cell proliferation and interleukin (IL)-2 production. This compartmentalisation of signaling opens the possibility that complementary CARs could be used to focus T-cell activation within the tumor microenvironment.
Here, we have tested this principle by co-expressing an ErbB2- and MUC1-specific CAR that signal using CD3ζ and CD28 respectively. Stoichiometric co-expression of transgenes was achieved using the SFG retroviral vector containing an intervening Thosea asigna peptide.
We found that “dual-targeted” T-cells kill ErbB2+ tumor cells efficiently and proliferate in a manner that requires co-expression of MUC1 and ErbB2 by target cells. Notably, however, IL-2 production was modest when compared to control CAR-engineered T-cells in which signaling is delivered by a fused CD28 + CD3ζ endodomain.
These findings demonstrate the principle that dual targeting may be achieved using genetically targeted T-cells and pave the way for testing of this strategy in vivo.
KeywordsAdoptive immunotherapy chimeric antigen receptor dual specificity targeting MUC1 ErbB2
This work was supported by a Breast Cancer Campaign Project Grant (2006NovPR18), the Guy’s and St Thomas’ Charity, Experimental Cancer Medicine Centre (King’s College London) and by Guy’s and the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC) award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust. CB is funded by the Oracle Cancer Trust at the Royal Marsden Hospital. SAE’s research is funded by the Institute of Cancer Research (ICR) and Cancer Research UK grant CA309/A8274 and funding provided via the NIHR specialist BRC award to the Royal Marsden NHS Foundation Trust in partnership with the ICR. We thank colleagues who have generously provided materials that facilitated this work, as indicated in the text.
Conflict of Interest Statement
The authors declare that they have no conflict of interest.
- 19.Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995–1004.PubMedCrossRefGoogle Scholar
- 23.Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med. 2011;3:95ra73.Google Scholar
- 32.Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1:123–7.PubMedCrossRefGoogle Scholar
- 38.Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 2001;61:1976–82.PubMedGoogle Scholar
- 41.Hombach AA, Abken, H. Costimulation by chimeric antigen receptors revisited: The T cell antitumour response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011: Article first published online: 29 MAR 2011 | doi: 10.1002/ijc.25960.